Toward the molecular dissection of peritoneal pseudomyxoma

Annals of Oncology

Volumn 27, Issue 11, 2016, Pages 2097-2103

  Pietrantonio, F ^a   Perrone, F ^a   Mennitto, A ^a   Gleeson, E M ^b   Milione, M ^a   Tamborini, E ^a   Busico, A ^a   Settanni, G ^a   Berenato, R ^a   Caporale, M ^a   Morano, F ^a   Bossi, I ^a   Pellegrinelli, A ^a   Di Bartolomeo, M ^a   de Braud, F ^a,c   Baratti, D ^a   Bowne, W B ^b   Kusamura, S ^a   Deraco, M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

GNAS; KRAS; Prognosis; Pseudomyxoma peritonei

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; GENE; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GNAS GENE; HUMAN; MALE; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; OVERALL SURVIVAL; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PROGNOSIS; THERMOTHERAPY;

CHROMOGRANIN; CISPLATIN; GNAS PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR MARKER;

ADULT; AGED; BIOMARKERS, TUMOR; CHROMOGRANINS; CISPLATIN; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); PSEUDOMYXOMA PERITONEI;

EID: 85002578535     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw314     Document Type: Article

References (19)

1. Smeenk RM, van Velthuysen ML, Verwaal VJ et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 2008; 34: 196-201.
2. Baratti D, Kusamura S, Nonaka D et al. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hypertermic intraperitoneal chemotherapy. Ann Surg 2009; 249: 243-249.
3. Bradley RF, Stewart JH, 4th, Russell GB et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006; 30: 551-559.
4. Austin F, Manavur A, Magesh S et al. Aggressive management of peritoneal Carcinomatosis from mucinous appendiceal neoplasm. Ann Surg Oncol 2012; 19: 1386-1393.
5. Kabbani W, Houlihan PS, Luthra R et al. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod Pathol 2002; 15: 599-605.
6. Lilleberg SL, Foster JM, Sharma P et al. Use of mutations analysis of pseudomixoma peritonei and appendiceal adenocarcinomas to identify somatic variants within MAPK, AKT and WNT signaling pathways: potential markers for focused treatment strategies. In 2009 ASCO Gastrointestinal Cancers Symposium. Abstract 334.
7. Shetty S, Thomas P, Ramanan B et al. KRAS mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. J Surg Res 2013; 180: 97-103.
8. Pietrantonio F, Maggi C, Fanetti G et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist 2014; 19: 845-850.
9. Nishikawa G, Sekine S, Ogawa R et al. Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms. Br J Cancer 2013; 108: 951-958.
10. Nummela P, Saarinen L, Thiel A et al. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. Int J Cancer 2015; 136: E282-E289.
11. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res 1996; 82: 235-253.
12. Chua TC, Moran BJ, Sugarbaker PH et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30: 2449-2456.
13. Baratti D, Kusamura S, Maggi C et al. In reply. Oncologist 2015; 20: e5.
14. Zauber P, Marotta S, Sabbath-Solitare M. GNAS mutations are associated with mucin production in low-grade appendiceal mucinous neoplasms, villous adenomas, and carcinomas. Hum Pathol 2015; 46: 339.
15. Bazan V, Migliavacca M, Zanna I et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 Kras mutations are associated with mucinous histotype. Ann Oncol 2002; 13: 1438-1446.
16. Singhi AD, Davison JM, Choudry HA et al. GNAS is frequently mutated in both lowgrade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival. Hum Pathol 2014; 45: 1737-1743.
17. Perrone F, Lampis A, Orsenigo M et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20: 84-90.
18. Vincenzi B, Cremolini C, Sartore-Bianchi A et al. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget 2015; 6: 31604-31612.
19. Liu X, Mody K, de Abreu FB et al. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin Chem 2014; 60: 1004-1011.